Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
226
resultados
Última actualización
04/10/2026 [06:50:00]
Resumen de: AU2025262086A1
A method is provided for producing a composition that includes a nanoparticle with at least one nucleic acid and at least one ionizable lipid. The method includes introducing a first composition that includes the at least one nucleic acid and a second composition that includes the at least one ionizable lipid into at least one reactor. The first composition and the second composition are introduced at a first flow rate and a second flow rate, respectively, therefore generating the nanoparticle in a reaction mixture. The method further includes filtering the nanoparticle from the reaction mixture via a single-pass tangential flow filter at a feed flux to provide a retentate, to produce the composition. The method may also include filtering the retentate through a sterile filtration membrane.
Resumen de: US20260297143A1
0000 Described herein are compositions and methods for treatment of conditions relating to expression and production of neurofibromin proteins. The disclosed compositions include nucleic acid molecules (e.g., messenger RNA, mRNA) providing optimized sequences, such as encoding for neurofibromin proteins or related derivatives or fragments thereof and useful for treating conditions associated with neurofibromatosis type 1. The disclosed compositions may be implemented in the form of nanoparticles including the nucleic acid molecules and suspended in a suitable carrier, such as an aqueous emulsion of a cationic lipid complex. The particle emulsion may be generated using an extrusion-based printing process. Administration of the disclosed compositions can result in expression of neurofibromin proteins or related derivatives or fragments thereof in mammals.
Resumen de: AU2025259015A1
Provided are compositions and methods for transfecting a cell of hematopoietic lineage, using a lipid nanoparticle (LNP) that includes a lipid mix composition including an ionizable lipid, the lipid mix composition encapsulating an HDR template DNA comprising a gene of interest for insertion into a desired chromosomal locus.
Resumen de: AU2025252092A1
The present disclosure relates to pharmaceutical compositions for editing genes that can be administered through inhalation, such as via nebulization. In particular, these compositions contain β-sitosterol instead of other sterols or steroids. These compositions may show improved gene editing performance with fewer editing errors and/or improved aerosolization compared to lipid nanoparticles with cholesterol.
Resumen de: US20260295075A1
0000 The invention relates to nanoparticles for Cas protein/gRNA ribonucleoprotein (RNP) complex, siRNA or PMO delivery comprising one or more Cas protein/gRNA RNP complex(es), siRNA(s) or PMO(s) as cargo; and a carrier comprising a sequence-defined T-shape lipo-oligomer comprising a tyrosine tripeptide and either a single artificial amino acid or two hydrophobic artificial amino acids at either side of a central lysine branching point and a hydrophobic tail comprising two fatty acids, wherein the artificial amino acid is an oligo(alkylamino) acid. The invention further relates to therapeutic and non-therapeutic uses thereof and to an in vitro method for transfecting mammalian cells.
Resumen de: US20260294836A1
0000 A method for targeting and tuning drug release in a human or non-human subject includes monitoring release of one or more drugs from one or more nanocomposites administered to the subject and applying precision-controlled optical stimulus to an area of the subject hosting the one or more nanocomposites to accelerate release of the one or more drugs from the one or more nanocomposites.
Resumen de: US20260294811A1
0000 The present disclosure provides an amino acid backbone ionizable lipid, preparation method thereof and application method therefor. The amino acid backbone ionizable lipid is modified with amino acids as a core, has many ester groups and peptide bonds, and can be quickly hydrolyzed by enzymes after effectively releasing RNA in vivo. The amino acid backbone ionizable lipid has four tail structures, which can increase a cross-sectional area of lipid tails, help RNA and other drugs escape from endosomes, and enhance transfection efficiency. A charge of the ionizable lipid is electrically neutral under physiological conditions, reducing a cytotoxicity caused by excessive positive charges, thereby increasing stability of lipid nanoparticles, helping to prolong circulation time of loaded nucleic acid drugs and improving pharmacokinetic characteristics.
Resumen de: AU2025236954A1
The present application provides lipid nanoparticles comprising an ionizable lipid, a phospholipid, a structural lipid, and a PEG lipid. The lipid nanoparticles of the present application enable encapsulation and delivery of a therapeutic/prophylactic agent, safely deliver the therapeutic/prophylactic agent to a targeted position, and enable high expression, thereby exerting the effect of the therapeutic/prophylactic agent.
Resumen de: AU2025237572A1
Community-associated and hospital acquired infections caused by bacteria and viruses on surfaces are global challenges to human health. New strategies that offer non-specific and broad protection are urgently needed. Irradiated cerium nanoparticles IrCNPs are provided which optionally are synthesized with a metal such as silver. These nanoparticles are designed to have superior function due to a higher trivalent (Ce3+) surface fraction, which produces high potency and residual effects on a variety of surfaces. Preferred IrCNPs can rapidly and completely eradiate Pseudomonas aeruginosa, Staphylococcus aureus, and methicillin resistant S. aureus, both species and biofilm, within 3 hours of exposure, and are effective against viruses as well.
Resumen de: US20260294835A1
0000 The present invention relates to a production method for a lipid nanoparticle, the method including: a step of dissolving a hyaluronic acid derivative in an aqueous solvent to form an aqueous phase; a step of dissolving a phospholipid in an organic solvent to form an oil phase; and a step of dropping and dispersing the oil phase into the aqueous phase, wherein the hyaluronic acid derivative is represented by a following general formula (1):
0000
wherein, in the general formula (1), R<1>, R<2>, R<3>, R<4>, and R<5 >each independently represent a hydroxy group or a group represented by —O—CH<2>—CH(OH)—CH<2>—OR<6>; R<6 >represents a linear or branched alkyl group or alkenyl group; and n represents an integer of 1 or more and 2500 or less, provided that a case where R<1>, R<2>, R<3>, R<4>, and R<5 >are all hydroxy groups is excluded.
Resumen de: US20260295069A1
0000 The present disclosure relates to nucleic acid-peptide-nucleic acid conjugate molecules and to methods for synthesizing nucleic acid-peptide-nucleic acid conjugate molecules. In some embodiments, a method for synthesizing a nucleic acid-peptide-nucleic acid conjugate molecule using proximity-enhanced synthesis includes covalently linking a peptide with a first nucleic acid strand via a first reaction, hybridizing the first nucleic acid strand with a second nucleic acid strand to bring the second nucleic acid strand in proximity to the peptide, and covalently linking the peptide with the second nucleic acid strand via a second reaction to provide the nucleic acid-peptide-nucleic acid conjugate molecule. In some embodiments, the peptide of the nucleic acid-peptide-nucleic acid conjugate molecule is a substrate for cleavage by an enzyme, such as matrix metalloproteinase-8 (MMP-8). Exemplary applications of the nucleic acid-peptide-nucleic acid conjugate molecule for drug delivery, molecular assembly of hybrid structures, and constraining the peptide to a biologically active conformation are also disclosed.
Resumen de: US20260294902A1
0000 A nanosystem and methods of treating, including prophylactically, coronavirus infections, such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by administering such nanosystem to a patient is presented. The nanosystem may be comprised of a single or a combination of therapeutic agents, optionally encapsulated in a nanoparticle having a targeting moiety directed to the particular coronavirus. For CoV-2 infections, at least one therapeutic agent, such as the dual DPP4/ACE2 inhibitor sitagliptin, may optionally be encapsulated within a nanoparticle having a fatty acid such as linoleic acid, as the targeting moiety. Administration can occur intranasally prior to infection for prophylactic treatment or post-infection for treatment of the viral infection.
Resumen de: US20260294833A1
This invention provides a pharmaceutical composition comprising an agent that can bind Siglec receptors on cell surface. This invention also provides the method of preparing said pharmaceutical composition and the use thereof.
Resumen de: AU2025230986A1
The purpose of the present invention is to provide a lipid nanoparticle that makes it possible to efficiently introduce a drug into a cell, and a constituent lipid of this lipid nanoparticle. Provided are: a compound represented by general formula (I), (II), or (III); a salt or stereoisomer thereof; and a lipid nanoparticle containing the same as a constituent lipid.
Resumen de: AU2025226097A1
Provided are gene therapy vectors designated MEV-GTVs, which are MEVs that contain an ITR-containing plasmid (also referred to as a minigene plasmid) that comprises Inverted Terminal Repeats (ITRs), such as viral ITRs, and nucleic acid encoding a product of interest, and optionally regulatory sequences. The ITRs serve to circularize the minigene plasmid. The plasmids do not contain additional viral components, so that resulting DNA is not encapsulated in a viral capsid or envelop and is not replicated by viral genes. The plasmids can be inserted into bacterial plasmids for propagation.
Resumen de: AU2025237119A1
Disclosed herein are methods and recombinant partially ordered polypeptides for repairing nerve injuries, such as a peripheral nerve injury. The methods and polypeptides can take advantage of temperature-dependent phase transition behavior of the polypeptide to provide biocompatible, porous scaffolds for beneficial outcomes in nerve repair. An example method includes administering a recombinant partially ordered polypeptide to a location of a nerve injury in a subject. An example recombinant partially ordered polypeptide includes a plurality of disordered domains, a plurality of structured domains, and an optional neuroregenerative domain.
Resumen de: AU2025224446A1
Disclosed herein are methods and compositions for the in vivo modification of cell genomes involving delivery of different components of gene editing components from different vectors. The methods and compositions target a heterologous polynucleotide to a target cell-specific locus for insertion into the genome, and for expression of a heterologous polypeptide in place of a native gene. The methods and compositions may be used in the treatment of disease.
Resumen de: US20260295048A1
0000 A magnetic hydrogel material with both bactericidal property and thermoresponsive contractility, a preparation method and an application thereof are provided. The magnetic hydrogel material adopts a poly(N-isopropylacrylamide) (PNIPAm) copolymerized polyacrylamide (PAm) double-network hydrogel as a matrix. Nano clay is grafted on the matrix to form a copolymer double-network hydrogel with thermoresponsive contractility, and a magnetic substance and tannic acid are doped in the copolymer double-network hydrogel to obtain the magnetic hydrogel material. The PNIPAm copolymerized PAm double-network hydrogel is formed through a radical polymerization reaction of N-isopropylacrylamide and acrylamide. The magnetic hydrogel material has both bactericidal property and mechanical loading property. The magnetic hydrogel material can effectively kill Staphylococcus aureus and Escherichia coli, and promote the healing of the infected diabetic wounds through bactericidal property and sustained mechanical loading on wounds.
Resumen de: US20260294807A1
This disclosure relates to compositions and methods for treating vascular disorders, including, for example, arteriovenous fistula (AVF) failure, stenosis, restenosis, and atherosclerosis.
Resumen de: US20260294825A1
0000 The present invention relates to a microfluidic platform for producing lipid nanoparticles (LNPs), which comprises a microfluidic channel for producing lipid nanoparticles inside using centrifugal force, at least one inlet configured to supply a fluid into the microfluidic channel, and at least one outlet configured to discharge the fluid from the microfluidic channel, the platform being provided in the form of a disk member.
Resumen de: US20260295071A1
A micro/nanoparticle formed of self-assembling micro/nanoparticle forming components, wherein at least one self-assembling micro/nanoparticle forming component is a cationic micro/nanoparticle forming component and at least one is an alginate oligomer which has at least 70% mannuronate residues, and the micro/nanoparticle further includes a molecule of interest, optionally wherein the molecule of interest is covalently bound to one or more of the self-assembling micro/nanoparticle forming components. Also disclosed are methods for translocating a cationic micro/nanoparticle across a mucus layer including contacting the mucus layer with at least one alginate oligomer, the alginate oligomer having at least 70% mannuronate residues, together with the cationic micro/nanoparticle; or contacting the cationic micro/nanoparticle with an alginate oligomer having at least 70% mannuronate residues thereby forming a micro/nanoparticle carrying the alginate oligomer, and contacting the mucus layer with the micro/nanoparticle.
Resumen de: US20260294830A1
Among other things, in general, polymer-lipid nanoparticles (PLNPs) are disclosed that have charge switching properties which allow for efficient release of payloads in the pH environment of the endosome. PLNPs and methods of manufacture thereof are disclosed for charge switchable PLNPs having an anionic polymeric shell surrounding ionizable cationic lipids (also potentially including helper lipids and cholesterol) that are in complex with a cargo (such as, in a non-limiting example, therapeutically useful nucleic acids).
Resumen de: US20260294829A1
0000 The present disclosure relates to a nucleic acid-lipid nanoparticle composition and a lyophilized preparation thereof, and further relates to a preparation method for the composition and a use of the composition. The nucleic acid-lipid nanoparticle composition of the present disclosure comprises lactate, so that the stability of nucleic acid-lipid nanoparticles is improved in a lyophilization process and a prepared lyophilized preparation. According to the present disclosure, the total time of a freeze-drying process for the nucleic acid-lipid nanoparticles can be shortened, and energy consumption and the time cost of product scale-up production can be greatly reduced; the rehydration of lyophilized nucleic acid-lipid nanoparticles is quick, and the total amount of nucleic acids, the encapsulation efficiency, and the nucleic acid integrity are high; in addition, a lyophilized and rehydrated preparation has cell transfection efficiency not significantly different from that of a non-lyophilized nucleic acid-lipid nanoparticle stock solution, and has a high in vivo immune response, even exceeding that of the non-lyophilized nucleic acid-lipid nanoparticle stock solution.
Resumen de: US20260295035A1
Provided herein are fragments of the gE protein of varicella-zoster virus and therapeutic nucleic acid molecules for managing, preventing and/or treating a disease or disorder caused by varicella-zoster virus or by infection therewith. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
Nº publicación: US20260295034A1 01/10/2026
Solicitante:
THE SCRIPPS RESEARCH INST [US]
The Scripps Research Institute
Resumen de: US20260295034A1
0000 The present invention relates to coronavirus immunogens and a vaccine platform for coronaviruses. In particular, the invention relates to a non-naturally occurring polypeptides comprising an engineered pathogen S2 subunit and a secretion signal sequence, nucleic acids encoding the same, vectors containing the nucleic acids, nanoparticles containing the polypeptides, nucleic acids or vectors, cells containing the nanoparticles, polypeptides, nucleic acids or vectors, pharmaceutical compositions comprising the cells, nanoparticles, polypeptides, nucleic acids or vectors, vaccines comprising the pharmaceutical compositions and methods for immunization with the vaccines.
BOPI
Sede Electrónica
